Source: Annual Congress 2002 - Current issues in lung transplantation
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
T. Hentschel, E. Czeslick, G. Dreisbach, H. Bromber, A. Simm, I. Friedrich, A. Sablotzki (Halle, Germany). Iloprost (IP) shows better hemodynamic effects in heart transplant candidates than NO. Eur Respir J 2002; 20: Suppl. 38, 2152

Member's Comments

No comment yet.

Related content which might interest you: Rapid switch from epoprostenol (EPO) to intravenous treprostinil (TRE) in patients with pulmonary arterial hypertension (PAH): safety, efficacy, and treatment satisfaction Source: Annual Congress 2009 - Pulmonary arterial hypertension Year: 2009 Influence of cardiac allograft vasculopathy (CAV) on exercise performance post cardiac transplant Source: Eur Respir J 2002; 20: Suppl. 38, 408s Year: 2002 Bosentan delays time to clinical worsening (TTCW) and improves haemodynamics in who class II pulmonary arterial hypertension (PAH) patients: EARLY study results Source: Annual Congress 2007 - Clinical aspects of pulmonary arterial hypertension Year: 2007 Effects of pulmonary rehabilitation following single (SLTX) or double (DLTX) lung transplantation Source: Eur Respir J 2001; 18: Suppl. 33, 355s Year: 2001 Incorporating patients with chronic heart failure (CHF) into pulmonary rehabilitation (PR): a propensity matched analysis Source: Virtual Congress 2020 – Optimising the benefits of pulmonary rehabilitation Year: 2020 Time-course changes in pulmonary haemodynamics in patients with idiopathic pulmonary fibrosis (IPF) waiting for lung transplantation (LT) Source: Eur Respir J 2004; 24: Suppl. 48, 668s Year: 2004 Effects of pulmonary rehabilitation (PR) in lung transplantation (LTx) candidates with Indication for non invasive ventilation (NIV) Source: Annual Congress 2010 - Physical activity, exercise regimes and outcomes for chronic respiratory disease Year: 2010 Evaluation of the biological effects of atorvastatin in lung transplant recipients Source: Annual Congress 2007 - New insights into clinical lung transplantation Year: 2007 Acute effect of sildenafil (PDE-5) on cardiopulmonary interactions in patients with pulmonary arterial hypertension (PAH) secondary to pulmonary fibrosis Source: Annual Congress 2008 - Pulmonary hypertension II Year: 2008 Impact of bisphosphonate (BP) use on lung function decline and treatment response in patients (pts) with idiopathic pulmonary fibrosis (IPF) Source: Virtual Congress 2020 – News on diagnosis and therapy of idiopathic pulmonary fibrosis Year: 2020 SERCA2a gene therapy ameliorates pulmonary hypertension in a pig model: comparison of different delivery methods and therapeutic effect Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension Year: 2020 Epoprostenol therapy for primary pulmonary hypertension after rejection of a single donor lung Source: Eur Respir J 2003; 21: 192-194 Year: 2003 Acute hemodynamic effects of non-invasive ventilation (NIV) in patients with exacerbation of congestive heart failure (CHF) Source: Eur Respir J 2005; 26: Suppl. 49, 550s Year: 2005 Internal validation of a model to predict the risk of short-term (10 days) adverse outcomes in patients with pulmonary embolism (PE) Source: Annual Congress 2006 - Pulmonary embolism Year: 2006 Changes in biomarkers with nintedanib and sildenafil in subjects with IPF in the INSTAGE trial: subgroup analysis by right heart dysfunction (RHD) Source: Virtual Congress 2020 – Biomarkers and mechanistic aspects of idiopathic pulmonary fibrosis Year: 2020 Long-term outcomes in incident pulmonary arterial hypertension (PAH) patients initiated with triple combination therapy including parenteral prostacyclin (PGI2) Source: Virtual Congress 2020 – Updated assessment and treatment of pulmonary arterial hypertension Year: 2020 Risk stratification in patients with pulmonary arterial hypertension (PAH) and candidates for lung or heart-lung transplantation Source: Virtual Congress 2021 – All about pulmonary arterial hypertension Year: 2021 Pulmonary hemodynamics and remodeling of the right heart in patients with COPD, depending on the risk group. Source: International Congress 2019 – Cardiovascular comorbidities in COPD Year: 2019 Non-invasive parameters can predict out of proportion pulmonary hypertension (PH) in conjunction with heart failure and preserved systolic function (HFPSF) in patients with moderate to severe PH Source: Annual Congress 2010 - Pulmonary hypertension updates Year: 2010 A new method to estimate the long-term effect of immunosuppressants and vasodilator therapies on lung function outcomes in systemic sclerosis patients Source: Virtual Congress 2020 – Predictive markers of progression in connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis Year: 2020